budesonide for crohn’s disease

Budesonide delivers 42-67% remission rates in active Crohn’s disease, making it a standard pharmaceutical choice. Yet corticosteroid dependency, tachyphylaxis, and systemic side effects leave thousands seeking complementary paths. This comparison examines clinical budesonide data against herbal protocols proven to induce remission without steroid exposure evaluating efficacy timelines, safety profiles, cost trajectories, and real-world patient outcomes […]